Warning: CMEcorner.com will not work properly with JavaScript disabled! Please enable javascript before proceeding.
Warning: CMEcorner.com will not work properly with JavaScript disabled! Please enable javascript before proceeding.
This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit,
click here
.
Depression and Anxiety in the Elderly: Optimizing Pharmacotherapy
Release Date: January 30, 2008
Medical Communications Media, Inc.
This program has been developed specifically for pharmacists and nurses who care for patients with depression and anxiety in the long-term care setting.
1 contact hour
Audioconference
Depressive symptoms are extremely common in nursing homes. A myriad of factors are associated with nursing home depression, and depression is linked to increased morbidity in long-term care residents. Clinicians often have difficulty diagnosing depression and anxiety in the senior care setting, especially when the patient is affected by dementia. Healthcare providers working in the long-term care sector need continuing education on screening techniques and treatment and management strategies, with particular emphasis on the drug interactions/polypharmacy issues that remain challenging in this population. This program is designed to help educate healthcare providers about appropriate pharmacologic approaches to managing depression in the elderly population. By providing objective, evidence-based education on depression and anxiety, clinical outcomes in the senior care setting may significantly improve.
Upon completion of this educational activity, the participant should be able to:
1.
Outline strategies to enhance the recognition and diagnosis of depression and anxiety in the elderly
2.
Review the role of various pharmacologic agents for depression and anxiety
3.
Describe the challenges of comorbidities and polypharmacy when prescribing antidepressants and anxiolytics in the senior care setting
4.
Discuss the monitoring for common side effects associated with these agents
Alan Berkowitz, MD
Assistant Clinical Professor
Department of Psychiatry
University of California
San Diego
Raymond C. Love, PharmD, BCPP, FASHP
Professor
School of Pharmacy
Associate Professor
Department of Psychiatry
University of Maryland School of Medicine
Baltimore
In accordance with the guidelines set forth by the Accreditation Council for Pharmacy Education, it is the policy of the American Society of Consultant Pharmacists to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker¹s interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Alan Berkowitz, MD,
discloses that he has served as a consultant and has been a member of the speaker's bureau for Abbott Laboratories, Forest Pharmaceuticals, Inc., Pfizer Inc, and Takeda Pharmaceuticals North America, Inc.
Raymond C. Love, PharmD, BCPP, FASHP,
has no conflicts of interest to disclose.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Pharmacy Continuing Education:
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program (ACPE # 203-999-08-001-C01-P) was developed by ASCP and is approved for 1.0 Contact Hour (0.1 CEU).
Nursing Continuing Education:
NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1087. This program provides 1 contact hour by NADONA/LTC.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. A statement of credit will be available immediately if the post-test and evaluation are completed online or within 6 weeks if they are sent by mail.
Supported by an educational grant from Forest Pharmaceuticals, Inc.
$0.00
